First Trust Advisors Sells Amgen Shares

Institutional investor reduces stake in biotech giant

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

First Trust Advisors LP decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 8.6% during the 3rd quarter, according to the company's recent 13F filing with the Securities & Exchange Commission. The fund now owns 488,781 shares of the medical research company's stock, down from 534,829 shares previously.

Why it matters

Amgen is a major biotech company with a diverse portfolio of drugs and a significant institutional investor base. Changes in ownership by large funds can signal shifts in market sentiment or portfolio rebalancing, which can impact the stock price and trading volume.

The details

First Trust Advisors sold 46,048 shares of Amgen during the third quarter, reducing its total stake to approximately 0.09% of the company's outstanding shares. The fund cited portfolio adjustments as the reason for the sale. Amgen's stock price has risen steadily over the past year, up around 15% as the company continues to grow its revenue and earnings.

  • First Trust Advisors filed its 13F report for the 3rd quarter of 2026 on March 9, 2026.

The players

First Trust Advisors LP

A global asset management firm that provides investment solutions to financial advisors and institutions.

Amgen Inc.

A leading biotechnology company that discovers, develops, manufactures and delivers human therapeutics to treat serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

This transaction reflects ongoing portfolio management by a major institutional investor in the biotech sector, which can impact the trading dynamics of Amgen's stock even as the company continues to execute on its growth strategy.